Home ›
Sarcoma Trials ›
NCT05755113
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
A Phase IIa open label study evaluating the preliminary efficacy of intratumoural tigilanol tiglate in advanced and/or metastatic soft tissue sarcoma of the extremities and body wall.
Trial Details
NCT ID NCT05755113
Phase PHASE2
Sponsor QBiotics Group Limited
Status RECRUITING
Cancer Type Sarcoma
Interventions
Locations (sample) New York, New York, United States|40.71427,-74.00597
Key Eligibility Criteria
Are willing and able to provide written informed consent for the study prior to any protocol-specific procedures and to comply with all local and s… Are ≥ 18 years of age on the day of providing informed consent. Have advanced and/or metastatic disease of the body wall or extremities that is amenable to intratumoural injection either by palpation or under ul… Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Sarcoma Trials on Trialify →